🔗 Share this article

Given that the US undertakes unprecedented changes to its immunization recommendations, one figure has surfaced somewhat surprisingly: Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by questioning COVID-19 shots throughout the pandemic and has zeroed in on potential fatalities after Covid vaccination in her recent position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Vaccine Schedule

Health officials planned to announce major changes to the childhood vaccination calendar earlier this month, bringing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would place the US out of step with many the international standard with no evidence for benefit. The planned update has been delayed until the next year.

Instead of the director of the vaccine center, Høeg is listed to present at the event. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to lead the office this year.

A Shift at the FDA

This interim role could signify a closer partnership between the drug and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a greater focus upon reevaluating previously authorized immunizations at the FDA.

Høeg has frequently advocated for halting certain pediatric shot schedules in the US in order to be more similar to Denmark, a nation with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccines – usually the responsibility of Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Background

The appointee has little discernible background in drug development, oversight or management, which has been customary for former heads of the biologics center. She has been employed at the FDA as a key advisor to the commissioner and CBER since March.

“She appears not to have the necessary background” for leading the CDER, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in leading a sizeable institution. She lacks background in drug approvals.”

Former heads of the center would “grasp laws and regulations and the underlying principles of drug development”, said Janet Woodcock. “Objectively, she lacks the type of experience that prior appointees who ran CBER have had.”

The drug center has an enormous range of responsibilities at the FDA, Woodcock emphasized.

“Everybody just focuses on the new drug program, but the generic program authorizes numerous generic drugs. There’s a biologic copycat branch, over-the-counter program and other areas, and every single one need to be managed,” she noted. “The responsibility you overlook, that is the part that I always told people is going to bite you.”

There is also, a substantial management element to the job, which oversees more than 5,000 employees. “It’s a massive administrative position, if you execute it properly,” Woodcock concluded.

Response and Contentious Programs

When asked about concerns about Høeg’s qualifications and whether this appointment signifies greater collaboration among FDA leaders on immunizations, a spokesperson said that the “inquiries are based on incorrect presumptions”.

“Her resume aligns with the functions of her position,” the representative said, noting the time Dr. Høeg spent advising the agency head on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the agency head's controversial expedited review system, a disputed expedited drug-approval program that allegedly concerned her preceding directors. “By what process are these drugs being chosen for this voucher program? Who makes the calls?” Dr. Howard said. “There is a lot of secrecy occurring at the regulatory body right now.”

Overall, he said, “the FDA looks to be trending towards less stringent oversight of pharmaceuticals, with the exception of immunizations.”

Documented Past Work on Immunizations

Regarding vaccines, Høeg has a more documented, if troubling, history, some experts have noted. She published a research paper using unconfirmed volunteer-provided data to estimate the incidence of heart inflammation following COVID-19 vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Included in her “wish list” for the new government encompassed altering regulations for novel immunizations and ending “unnecessary” immunizations, she stated post-election on a audio program. At the FDA, Dr. Høeg has allegedly proposed preventing young men from obtaining COVID-19 vaccines.

“She is an thorough dogmatist who begins with her conclusions and works backwards to fit the science in a very deceptive, dishonest manner,” Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of other skeptics, {like|